2020
DOI: 10.1055/s-0040-1712545
|View full text |Cite
|
Sign up to set email alerts
|

Asymptomatic Presacral Paraganglioma: Management of an Unpredictable Intraoperative Finding

Abstract: Paragangliomas are rare neuroendocrine tumors originating from the embryological neural crest. We report a rare case of a patient with an asymptomatic presacral mass (incidentaloma) who experienced an unpredictable intraoperative hypertensive crisis after manipulation of the tumor. Presacral neoplasms pose a diagnostic and therapeutic challenge due to their obscure anatomical location and the difficulty in performing an R0 excision. Furthermore, the management of asymptomatic paragangliomas requires a high lev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 14 publications
0
1
0
Order By: Relevance
“…Following an R0 resection, patient surveillance requires plasma catecholamines and free metanephrines, urinary levels of catecholamines, VMA, total and fractionated metanephrines. These should be measured every three months during the first year, every six months until the third year, and then annually for up to 10 years (8). CT abdominal scan, abdominal MRI, and scintigraphy performed with 123-I labeled metaiodobenzylguanidine (MIBG) is essential in the assessment surveillance of the patients for metastatic disease, tumor recurrence, or delayed appearance of multiple primary tumors (15).…”
Section: Discussionmentioning
confidence: 99%
“…Following an R0 resection, patient surveillance requires plasma catecholamines and free metanephrines, urinary levels of catecholamines, VMA, total and fractionated metanephrines. These should be measured every three months during the first year, every six months until the third year, and then annually for up to 10 years (8). CT abdominal scan, abdominal MRI, and scintigraphy performed with 123-I labeled metaiodobenzylguanidine (MIBG) is essential in the assessment surveillance of the patients for metastatic disease, tumor recurrence, or delayed appearance of multiple primary tumors (15).…”
Section: Discussionmentioning
confidence: 99%